IDRA - Shares of Idera Pharmaceuticals Inc. (IDRA) Have Fallen Below Previous 52-Week Low

Shares of Idera Pharmaceuticals Inc. (NASDAQ:IDRA) traded at a new 52-week low today of $1.04. Approximately 6.3 million shares have changed hands today, as compared to an average 30-day volume of 5.5 million shares.

Idera Pharmaceuticals Inc is a clinical-stage biopharmaceutical company involved in the discovery, development, and commercialization of innovative therapeutics for oncology and rare diseases. The company has developed two distinct proprietary drug-discovery technology platforms: Toll-like receptor and third-generation antisense technology. The Toll-like receptor technology helped the company create synthetic oligonucleotide-based drug candidates.

There is potential upside of 28.1% for shares of Idera Pharmaceuticals Inc. based on a current price of $1.04 and an average consensus analyst price target of $1.33.

In the past 52 weeks, shares of Idera Pharmaceuticals Inc. have traded between the current low of $1.04 and a high of $6.14 and is now at $1.04.

Receive IBN Spotlights - "Bite Size" Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About InvestorBrandNetwork (IBN)
InvestorBrandNetwork (IBN) consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer